GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. Ozempic® acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.1
Once-weekly Ozempic® mechanism of action
GLP-1 RA stimulates the body’s own insulin secretion
How Ozempic® works in the body:

Stimulates insulin secretion
Ozempic® lowers fasting and postprandial blood glucose by stimulating insulin secretion in a glucose-dependent manner. With Ozempic®, the insulin secretion rate in patients with type 2 diabetes was similar to that of healthy subjects.1,2
See study design below.

Lowers glucagon secretion
Ozempic® lowers glucagon secretion in a glucose-dependent manner.1

Minor delay in gastric emptying
Ozempic® causes a minor delay in gastric emptying, thereby reducing the rate at which glucose appears in circulation postprandially.1

Ozempic® is a GLP‑1 analogue with 94% sequence homology to human GLP‑11
Structural modifications of the Ozempic® molecule result in decreased renal clearance and protection from metabolic degradation.1



Ozempic® delivers weeklong coverage1
~7 days | Elimination half-life of ~7 days.

4 to 5 weeks
Steady-state plasma concentrations achieved following 4 to 5 weeks of once-weekly administration.
In a pharmacodynamic study
Ozempic® provided similar insulin response to people without type 2 diabetes1,2
Insulin response to a graded glucose infusion test at 12 weeks1,2,a



aA continuous glucose infusion was adjusted over a 3-hour period to achieve target glucose levels from 90 to 216 mg/dL, increasing by increments of 18 mg/dL every 25 minutes.

Study design:
A 12-week, single-center, randomized, double-blind, placebo-controlled, parallel-group trial in 75 adult patients with type 2 diabetes. To examine the effects of Ozempic® 1 mg on different aspects of beta-cell response, primarily first- and second-phase insulin secretion, with a secretion rate as evaluated by a graded glucose infusion test, as a secondary endpoint. A comparator group of healthy participants (who did not receive treatment) was included in the study.2
Results:
With Ozempic®, the insulin secretion rate with type 2 diabetes was similar to that of healthy subjects.2
Ozempic® is dosed once weekly
Ozempic® has gradual dose escalation designed to help patients adjust to therapy.1,a Patients should administer Ozempic® once weekly with or without meals.

Text: double click to edit.
Help patients realize the potential with Ozempic®
